A staff works at a laboratory of BGI, China's top gene-sequencing provider, in Shenzhen, south China's Guangdong Province, June 25, 2016. (Xinhua/Mao Siqian)
The Genome Program will be executed and delivered by the Abu Dhabi-based tech giant Group 42 in collaboration with companies including BGI.
SHENZHEN, Dec. 12 (Xinhua) -- China's top gene-sequencing provider BGI will participate in the Genome Program, which aims to use genomic data to improve health outcomes in the United Arab Emirates (UAE), the company announced Wednesday.
The program plans to use large-scale genomic data to establish a health care system with predictable, preventative and individual-based medical treatment for the UAE people, according to the Shenzhen-based company.
It will be executed and delivered by the Abu Dhabi-based tech giant Group 42 in collaboration with companies including BGI.
BGI's technology, sequencing equipment and analytic capability stood out from the competition and will provide core technological support for the program, said Wang Jian, chairman of BGI.
BGI, founded in 1999, specializes in the research of genomics in the healthcare, agriculture and environmental sectors. ■
